Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 434 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Hemodialysis (ESRD) Clear all
Completed Not applicable Interventional

Transplant Navigator Dissemination

NCT01981603
View directory record Official record
Conditions
Kidney Transplant, Renal Failure Chronic Requiring Hemodialysis
Interventions
navigator
Other
Lead sponsor
Catherine Sullivan
Other
Eligibility
18 Years to 70 Years
Enrollment
1,926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Fort Wayne, Indiana • Lexington, Kentucky • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

NCT03799627
View directory record Official record
Conditions
Anemia, Dialysis-dependent Chronic Kidney Disease
Interventions
Vadadustat, Epoetin Alfa, Vadadustat TIW
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Fresno, California • Granada Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Not applicable Interventional

Treatment Choice and Outcomes for ESRD: Evidence From the First Year of a Nationwide Randomized Evaluation

NCT05005572
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Payment adjustment for home dialysis and transplant
Other
Lead sponsor
Amy Finkelstein
Other
Eligibility
66 Years and older
Enrollment
18,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

NCT05099445
View directory record Official record
Conditions
Renal Impairment, Hemodialysis
Interventions
INCB000928
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Rialto, California • Hialeah, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03612856
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB023- Dose 1, AB023-Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05624710
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 23, 2026, 9:21 AM EDT
Withdrawn Not applicable Interventional

Animal Assisted Intervention for Hemodialysis Outpatients

NCT06030050
View directory record Official record
Conditions
End-Stage Kidney Disease, Chronic Kidney Failure, Chronic Pain
Interventions
Animal-assisted intervention
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 23, 2026, 9:21 AM EDT
Withdrawn Not applicable Interventional

Effects of Intensified Sodium Management in Hemodialysis Patients

NCT01015313
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
intensive sodium management
Other
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 4 Interventional

Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

NCT00294866
View directory record Official record
Conditions
Kidney Failure
Interventions
Paricalcitol
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Evergreen Park, Illinois • Kalamazoo, Michigan • West Orange, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2010 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

NCT02504294
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Epoetin Hospira Arm, Standard of Care Arm, IV Iron
Biological · Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
42
States / cities
Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Jul 23, 2026, 9:21 AM EDT
Not listed No phase listed Observational

An Observational Study of Pruritus Amongst Hemodialysis Patients

NCT00715260
View directory record Official record
Conditions
Pruritus, Kidney Failure, Chronic, Hemodialysis, Chronic Disease
Interventions
Not listed
Lead sponsor
Acologix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Augusta, Georgia • Metaire, Louisiana • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2008 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

NCT05836220
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Kidney Disease
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Anaheim, California • Chula Vista, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Not applicable Interventional Results available

Post-Approval Study for the FLAIR Endovascular Stent Graft

NCT00677235
View directory record Official record
Conditions
Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Interventions
FLAIR Endovascular Stent Graft, PTA
Device · Procedure
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bamberg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 23, 2026, 9:21 AM EDT
Completed No phase listed Observational Results available

Deprescribing for Older Dialysis Patients

NCT03631290
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Deprescribing Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 23, 2026, 9:21 AM EDT
Not listed No phase listed Observational

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

NCT05439174
View directory record Official record
Conditions
End-stage Renal Disease, Malnutrition; Protein
Interventions
Intradialytic Parenteral Nutrition
Other
Lead sponsor
Patient Care America
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

NCT01435174
View directory record Official record
Conditions
End-stage Renal Disease, Cardiovascular Disease
Interventions
Ranolazine, Pharmacokinetic Blood and Dialysate Sampling, QT Interval
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

NCT00679991
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
PRT-201
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Portland, Maine + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

NCT01630889
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 1 Interventional

Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis

NCT01739660
View directory record Official record
Conditions
Chronic Kidney Disease Stage 5
Interventions
Pegloticase
Drug
Lead sponsor
Savient Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Jul 23, 2026, 9:21 AM EDT
Completed No phase listed Observational

Blood Volume Analysis and Related Outcomes in Hemodialysis

NCT01679249
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Not listed
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Not applicable Interventional

Vitamin D Effect on Calcium Absorption on Persons on Hemodialysis

NCT01325610
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Vitamin D Deficiency
Interventions
cholecalciferol
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Jul 23, 2026, 9:21 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

NCT02159859
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Ertapenem
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 88 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Jul 23, 2026, 9:21 AM EDT
Completed No phase listed Observational

Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers

NCT00440908
View directory record Official record
Conditions
End Stage Renal Disease, Inflammation
Interventions
Not listed
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Jul 23, 2026, 9:21 AM EDT
Completed No phase listed Observational

Experience of Patients Starting Hemodialysis

NCT04988568
View directory record Official record
Conditions
ESRD
Interventions
None. This is a qualitative interview study.
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Los Gatos, California • Menlo Park, California • Milpitas, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Jul 23, 2026, 9:21 AM EDT